Synaptogenix Dividends and Buybacks

Dividend criteria checks 0/6

Synaptogenix does not have a record of paying a dividend.

Key information

n/a

Dividend yield

Buyback Yield

Total Shareholder Yield	0%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SNPX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNPX's dividend payments have been increasing.

Dividend Yield vs Market

Synaptogenix Dividend Yield vs Market

How does SNPX dividend yield compare to the market?
Segment	Dividend Yield
Company (SNPX)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (SNPX) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate SNPX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SNPX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SNPX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SNPX has not reported any payouts.

Synaptogenix Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Synaptogenix, Inc., Annual General Meeting, Dec 06, 2024

Insufficient new directors

Synaptogenix, Inc. announced that it has received $3.207 million in funding

Synaptogenix, Inc. announced a financing transaction

New major risk - Revenue and earnings growth

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix, Inc. (NasdaqCM:SNPX) acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.

New major risk - Share price stability

Synaptogenix, Inc., Annual General Meeting, Dec 20, 2023

New major risk - Shareholder dilution

New minor risk - Share price stability

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix, Inc. announced that it has received $15 million in funding

Synaptogenix, Inc. announced that it expects to receive $15 million in funding

We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

Synaptogenix, Inc., Annual General Meeting, Oct 11, 2022

Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Synaptogenix, Inc. announced that it has received $12.477342 million in funding

President recently bought US$83k worth of stock

Synaptogenix, Inc. announced that it expects to receive $12.499998 million in funding

Synaptogenix: The Next Big Thing In Alzheimer's

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

Synaptogenix provides update on phase 2b Alzheimer's disease trial

We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate

Synaptogenix, Inc. announced that it has received $14.0033 million in funding

Synaptogenix Announces Licensing Agreement with Stanford University; and Supply Agreement with Bryologyx, Inc

Synaptogenix announced that it expects to receive $14 million in funding

Synaptogenix Inc Announces CEO Changes

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies